- Home
- MNPR vs CPAC Comparison
MNPR vs CPAC Comparison
Compare MNPR & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNPR | CPAC |
|---|---|---|
| Founded | 2014 | 1949 |
| Country | United States | Peru |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Materials |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.6M | 580.5M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MNPR | CPAC |
|---|---|---|
| Price | $76.19 | $6.84 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 13 | 2 |
| Target Price | ★ $97.83 | $6.95 |
| AVG Volume (30 Days) | ★ 163.8K | 26.5K |
| Earning Date | 11-13-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 7.89% |
| EPS Growth | N/A | ★ 20.27 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $601,081,883.00 |
| Revenue This Year | N/A | $9.96 |
| Revenue Next Year | N/A | $1.70 |
| P/E Ratio | ★ N/A | $8.92 |
| Revenue Growth | N/A | ★ 6.18 |
| 52 Week Low | $21.00 | $5.10 |
| 52 Week High | $105.00 | $7.57 |
Technical Indicators
Market Signals| Indicator | MNPR | CPAC |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 46.60 |
| Support Level | $74.51 | $6.59 |
| Resistance Level | $79.31 | $6.85 |
| Average True Range (ATR) | 6.38 | 0.24 |
| MACD | -0.93 | 0.01 |
| Stochastic Oscillator | 6.10 | 80.88 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About CPAC Cementos Pacasmayo S.A.A. (Each representing five)
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.